CLINICAL_TRIALS
ClinicalTrials.gov record update
Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03520842
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:02.889872+00:00
- Published At
- 2023-08-01T00:00:00+00:00
- Record Updated At
- 2023-08-01
- Results Posted At
- 2023-08-01
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["KRAS Gene Mutation", "Metastatic Malignant Neoplasm in the Brain", "Recurrent Non-Small Cell Lung Carcinoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-08-01"- protocolSection.identificationModule.nctId
"NCT03520842"- protocolSection.identificationModule.officialTitle
"Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-08-01"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.